Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook January 14, 2025
Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe January 8, 2025
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease January 7, 2025
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium December 27, 2024
